BioAtla, Inc. (BCAB): Price and Financial Metrics
BCAB Price/Volume Stats
| Current price | $1.59 | 52-week high | $9.87 |
| Prev. close | $1.55 | 52-week low | $1.24 |
| Day low | $1.49 | Volume | 272,500 |
| Day high | $1.63 | Avg. volume | 502,176 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $2.61 | Market Cap | 76.22M |
BCAB Stock Price Chart Interactive Chart >
BioAtla, Inc. (BCAB) Company Bio
BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Latest BCAB News From Around the Web
Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.
BioAtla to Participate in the JMP Securities Hematology and Oncology SummitSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities Hematology and Oncology Summit, to be held virtually December 5–6, 2023. Format: Fireside chat and scheduled |
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLCSAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET. To register, click here. The event will feature Carl M. Gay, MD, PhD (MD Anderson Cancer Center), who will review the Phase 2 clinical trial data of mecbotamab ved |
BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call TranscriptBioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] Please be advised that this call is […] |
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressObserved additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023Observed new PRs with CAB-ROR2-ADC (BA3021) Q2W dosing regimen in the Phase 2 melanoma study and a new PR with BA3021 2Q3W in the Phase 2 head and neck studyInitiated Phase 2 CAB-CTLA-4 (BA3071) study; |
BioAtla to Participate in the Jefferies London Healthcare ConferenceSAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 14–16, 2023. Format: Fireside chat and one-on-one |
BCAB Price Returns
| 1-mo | -3.64% |
| 3-mo | -33.47% |
| 6-mo | -56.44% |
| 1-year | -83.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -80.73% |
| 2022 | -57.97% |
| 2021 | -42.28% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...